Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2017-02-16 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release announcing a conference call for the fourth quarter and full-year 2016 financial results. The document itself does not contain financial statements or detailed financial data but rather serves as an announcement of an upcoming event related to financial results. The length is short (1929 characters), and it primarily references a press release and a conference call. According to the rules, such documents are classified as Regulatory Filings (RNS) because they do not contain the actual financial report or transcript but are announcements or filings related to regulatory compliance and disclosures.
2017-02-16 English
13G/A
Major Shareholding Notification
2017-02-13 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by RedHill Biopharma Ltd., which is a report of a foreign private issuer pursuant to SEC rules. It includes a press release about enrollment completion in a clinical study. The document is short (1922 characters) and primarily serves as an announcement of a press release rather than containing detailed financial data or comprehensive reporting. Form 6-K filings are typically periodic reports for foreign issuers that do not correspond to annual or quarterly reports but rather provide updates or announcements. Given the nature and length, this filing fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2017-02-13 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-02-10 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about a presentation at an investor conference. The document length is short (1879 characters) and it primarily serves as an announcement of an event (presentation) rather than containing detailed financial data or a full report. Form 6-K filings are typically used for current reports by foreign private issuers and often include press releases or other material information. Given the content and length, this document is best classified as a Regulatory Filing (RNS) rather than an Investor Presentation (IP) or Annual/Interim Report.
2017-02-06 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release titled 'RedHill Biopharma Provides 2017 Semi-Annual Business Update.' Form 6-K is used by foreign private issuers to report material information between annual reports. The document length is 1872 characters, which is relatively short and mainly contains an announcement of a business update rather than detailed financial statements or comprehensive reports. It does not contain full financial data or detailed analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and often includes Form 6-K submissions.
2017-01-12 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.